JP2022530442A5 - - Google Patents

Info

Publication number
JP2022530442A5
JP2022530442A5 JP2021563165A JP2021563165A JP2022530442A5 JP 2022530442 A5 JP2022530442 A5 JP 2022530442A5 JP 2021563165 A JP2021563165 A JP 2021563165A JP 2021563165 A JP2021563165 A JP 2021563165A JP 2022530442 A5 JP2022530442 A5 JP 2022530442A5
Authority
JP
Japan
Application number
JP2021563165A
Other languages
Japanese (ja)
Other versions
JP2022530442A (ja
JPWO2020219774A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029656 external-priority patent/WO2020219774A1/en
Publication of JP2022530442A publication Critical patent/JP2022530442A/ja
Publication of JPWO2020219774A5 publication Critical patent/JPWO2020219774A5/ja
Publication of JP2022530442A5 publication Critical patent/JP2022530442A5/ja
Withdrawn legal-status Critical Current

Links

JP2021563165A 2019-04-24 2020-04-23 アントラサイクリン抗体薬物複合体およびその使用 Withdrawn JP2022530442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838267P 2019-04-24 2019-04-24
US62/838,267 2019-04-24
PCT/US2020/029656 WO2020219774A1 (en) 2019-04-24 2020-04-23 Anthracycline antibody-drug conjugates and uses thereof

Publications (3)

Publication Number Publication Date
JP2022530442A JP2022530442A (ja) 2022-06-29
JPWO2020219774A5 JPWO2020219774A5 (https=) 2023-05-01
JP2022530442A5 true JP2022530442A5 (https=) 2023-05-01

Family

ID=72940981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563165A Withdrawn JP2022530442A (ja) 2019-04-24 2020-04-23 アントラサイクリン抗体薬物複合体およびその使用

Country Status (4)

Country Link
US (1) US20220226493A1 (https=)
EP (1) EP3959242A4 (https=)
JP (1) JP2022530442A (https=)
WO (1) WO2020219774A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079215A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
CN120399078B (zh) * 2025-05-08 2026-03-06 上海天泽云泰生物医药股份有限公司 靶向cd117的纳米抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CA2531684C (en) * 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
US8722587B2 (en) * 2008-04-09 2014-05-13 The Trustees Of The University Of Pennsylvania Single chain fragment variable antibody libraries and uses thereof
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
CN107148429B (zh) * 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法
HK1249534A1 (zh) * 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
BR112018074453A2 (pt) * 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
CA3079215A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
CA3079897A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
WO2019234694A2 (en) * 2018-06-07 2019-12-12 Magenta Therapeutics, Inc. Therapeutic methods using antibody drug conjugates (adcs)
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
JP2022512781A (ja) * 2018-10-30 2022-02-07 マジェンタ セラピューティクス インコーポレイテッド 同種造血幹細胞移植の方法
EP3958909A4 (en) * 2019-04-24 2024-01-10 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF
EP3958899A4 (en) * 2019-04-24 2023-08-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND THEIR USES
CA3134319A1 (en) * 2019-04-24 2020-10-29 Rahul Palchaudhuri Anti-cd117 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2022530438A5 (https=)
JP2022530442A5 (https=)
JPWO2022259294A1 (https=)
BR202021022912U2 (https=)
CN305741514S (https=)
CN305537372S (https=)
CN305534820S (https=)
CN305533551S (https=)
CN305533390S (https=)
CN305531932S (https=)
CN305529800S (https=)
CN305529600S (https=)
CN305529585S (https=)
CN305529125S (https=)
CN305710984S (https=)
CN305527940S (https=)
CN305527895S (https=)
CN305527275S (https=)
CN305691070S (https=)
CN306105369S (https=)
CN305727317S (https=)
CN305680838S (https=)
CN306225288S (https=)
CN306200791S (https=)
CN306224957S (https=)